期刊文献+

反应结晶法制备超细环丙沙星颗粒

Preparation of micronized ciprofloxacin by reactive precipitation
下载PDF
导出
摘要 采用反应结晶法进行了环丙沙星微粉化实验,考察了反应物摩尔比,搅拌转速,氢氧化钠浓度等各个因素对微粉化过程的影响。实验得到适宜的微粉化条件为:盐酸环丙沙星与氢氧化钠的摩尔比为8∶1-10∶1,搅拌转速控制在15000 r/min左右,氢氧化钠浓度约为0.01 mol/L,对微粉化后的粉体分别用扫描电镜,X射线衍射分析和红外进行表征,结果表明制备所得到的环丙沙星干粉粒度约为1-2μm,结构和晶型均没有改变。 A simple method for formation of micronized ciprofloxacin particles by reactive precipitation has been developed. The effects of varying five critical parameters-molar ratio of reactants, concentration of NaOH solution, reaction temperature, stirring speed and drying method-on particle size and morphology are described. The optimum conditions for preparation of micronized ciprofloxacin were found to be: molar ratio of reactants in the range 8 - 10, stirring speed 15000 r/min, and concentration of NaOH 0.01 mol/L. The particle size of ciprofloxacin dry power shown by SEM can reach 1 - 2 μm. IR spectroscopy and X-ray diffraction showed that the molecular structure and crystallinity of ciprofloxacin did not change during the process.
出处 《北京化工大学学报(自然科学版)》 EI CAS CSCD 北大核心 2008年第3期19-22,共4页 Journal of Beijing University of Chemical Technology(Natural Science Edition)
基金 国家'863'计划(2006AA030202)
关键词 环丙沙星 微粉化 反应结晶 ciprofloxacin micronized reactive precipitation
  • 相关文献

参考文献7

二级参考文献47

  • 1[1]Timsina MP, Martin GP, Marriott C, et al. Drug delivery to the respiratory tract using dry powder inhalers[J]. Int J Pharm, 1994, 101 (1): 1 - 13.
  • 2[2]Komada F, Iwakawa S, Yamamoto N, et al. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung[J]. J Pharm Sci, 1994, 83(6): 863 - 867.
  • 3[3]Steckel H, Müller BW. In vitro evaluation of dry powder inhalers. Ⅰ. Drug deposition of commonly used devices [J]. IntJPharm, 1997, 154(1):19-29.
  • 4[4]Bell JH, Hartley PS, Cox JSG. Dry powder aerosols. Ⅰ .A new powder inhalation device[J]. J Pharm Sci, 1971,60(10): 1559 - 1564.
  • 5[5]Winfield AJ, Richards RME. Aerosols and other dosage forms- dry powder devices[A]. 2 nd ed. Pharmaceutical Practice[M], UK: Churchill Livingstone Press, 1998:170- 172.
  • 6[6]Newman SP, Hollingworth A, Clark AR. Effect of different modes of inhalation on drug delivery from a dry powder inhaler[J]. Int J Pharm, 1994, 102(2): 127 - 132.
  • 7[7]Davies PJ, Hanlon GW, Molyneux AJ. An investigation into the deposition of inhalation aerosol particles as a function of airflow rate in a modified ‘kirk lung'[J]. J Pharm Pharmacol, 1976, 28(12) :908- 911.
  • 8[8]Hickey AJ, Concessio NM. Descriptors of irregular particle morphology and powder properties[J]. Adv Drug Deliv Rev,1997, 26(1):29-40.
  • 9[9]Zeng XM, Pandhal KH, Martin GP. The influences of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols[J].Int J Pharm, 2000, 197(1/2) :41 - 52.
  • 10[10]Bennett FS, Carter PA, Rowley G, et al. Modificaton of electrostatic charge on inhaled carrier lactose particles by addition of fine particles[J]. Drug Dev Ind Pharm, 1999,25(1):99- 103.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部